VNRX
HEALTHCAREVolitionRX Ltd
$2.49+0.16 (+6.87%)PRE
Live · AMEX · May 9, Close
AI Insight
What's Moving VNRX Today?
No stock-specific AI insight has been generated for VNRX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.17$18.80
$2.49
Fundamentals
Market Cap$20M
P/E Ratio—
EPS$-4.40
Dividend Yield—
Dividend / Share—
ROE-7.3%
Profit Margin—
Debt / Equity—
Trading
Volume1.0M
Avg Volume (10D)—
Shares Outstanding8.1M
VNRX News
20 articles- VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in CatsYahoo Finance·May 6, 2026
- Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis TestingYahoo Finance·Apr 29, 2026
- VNRX: Zacks SCR Refreshes its Latest Report With Volition's Financials, Prices, EPS Estimates, Market Statistics and Target Price Adjusted for 1-for-20 Reverse-SplitYahoo Finance·Apr 28, 2026
- VNRX: Upcoming Milestones Expected in 2026; Year-End 2025 Results. Special Meeting of Stockholders Approves Reverse-Split. Subsequently, the Board of Directors authorized a 1-for-20 reverse-split that will become effective on April 28th.Yahoo Finance·Apr 27, 2026
- VolitionRx Announces Acceptance of Compliance Plan by NYSE AmericanYahoo Finance·Apr 23, 2026
- Volition Launches rNuQ™ Webshop Broadening Product RangeYahoo Finance·Apr 20, 2026
- VolitionRX Ltd (VNRX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...Yahoo Finance·Apr 3, 2026
- VolitionRx Limited Q4 2025 Earnings Call SummaryMoby·Apr 1, 2026
- VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business UpdateYahoo Finance·Mar 31, 2026
- VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in BelgiumYahoo Finance·Mar 31, 2026
- Volition Announces Mayo Clinic Study Demonstrates Nu.Q® Concentrations are Elevated in Trauma PatientsYahoo Finance·Mar 30, 2026
- Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer ConferenceYahoo Finance·Mar 26, 2026
- VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business UpdateYahoo Finance·Mar 25, 2026
- Volition Announces Detection of Over 95% of Early-Stage CancersYahoo Finance·Mar 25, 2026
- Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNAYahoo Finance·Mar 18, 2026
- VNRX: Review of Recent Events by Pillar; 4Q & Year End 2025 Results Expected in late March; Special Meeting of Stockholders to be held on March 31st to approve reverse-split. Almost US$2 million in cash funding received through the issuance of Convertible Note.Yahoo Finance·Mar 9, 2026
- VolitionRx announces automated Nu.Q Vet Cancer Test with Fujifilm Vet SystemsYahoo Finance·Mar 7, 2026
- Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet SystemsYahoo Finance·Mar 6, 2026
- VolitionRx Highlights Commercial Momentum and Multi-Pillar ExecutionYahoo Finance·Feb 25, 2026
- Volition Announces the Appointment of New Distributor for Nu.Q® DiscoverYahoo Finance·Feb 10, 2026
All 20 articles loaded
Price Data
Open$2.62
Previous Close$2.33
Day High$2.78
Day Low$2.34
52 Week High$18.80
52 Week Low$2.17
52-Week Range
$2.17$18.80
$2.49
Fundamentals
Market Cap$20M
P/E Ratio—
EPS$-4.40
Dividend Yield—
Dividend / Share—
ROE-7.3%
Profit Margin—
Debt / Equity—
Trading
Volume1.0M
Avg Volume (10D)—
Shares Outstanding8.1M
About VolitionRX Ltd
VolitionRx Limited, a multinational epigenetics company, is dedicated to developing blood tests to help diagnose a variety of cancers and other diseases globally. The company is headquartered in Austin, Texas.
HEALTHCAREMEDICAL DEVICES
Company Details
Security TypeStock
ExchangeAMEX
CurrencyUSD
Round Lot—
SICMEDICAL DEVICES
CIK—
Composite FIGI—
Share Class FIGI—